Center Laboratories Beheer

Beheer criteriumcontroles 1/4

De CEO Center Laboratories is Su-Chi Wang, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde NT$ 63.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 2.8 jaar.

Belangrijke informatie

Su-Chi Wang

Algemeen directeur

NT$4.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.1yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Nov 20

CEO

Su-Chi Wang

1.1yrs

Tenure

NT$4,722,000

Compensatie

Ms. Su-Chi Wang is Chairman of Lumosa Therapeutics Co. Ltd. from May 14, 2024. Ms. Wang Serves as Chief Executive Officer, Operations Management Office & Investment Office at Center Laboratories, Inc. sinc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Su-Chi Wang	CEO, Chief Investment Officer	1.1yrs	NT$4.72m	0.18% NT$ 63.9m
Min-Li Lien	Assistant Vice President of Legal Affairs Department	1.8yrs	NT$2.30m	geen gegevens
Jui-Pao Hsu	General President of Pharmaceutical Business	1.1yrs	NT$3.47m	0.68% NT$ 241.6m
Ching-Yu Tang	Head of Corporate Governance	no data	NT$1.87m	geen gegevens
Chiun-Yu Lin	Plant Director	7.8yrs	NT$2.28m	geen gegevens
An-Ni Mao	Manager of Finance & Accounting Department	1.9yrs	geen gegevens	geen gegevens
Hsiu Yueh Lin	Director of Administration Department	26.3yrs	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van 4123 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Su-Chi Wang	CEO, Chief Investment Officer	2yrs	NT$4.72m	0.18% NT$ 63.9m
Mei-Yueh Ho	Independent Director	4.4yrs	NT$735.00k	geen gegevens
Chun-Hong Chen	Director	4.4yrs	NT$55.00k	geen gegevens
Bo Zhi Zhang	Director	2.8yrs	geen gegevens	0.29% NT$ 103.5m
Jialing Lin	Director	2.8yrs	geen gegevens	0.71% NT$ 253.5m
Chang-Hai Tsai	Director	2.5yrs	NT$55.00k	geen gegevens
Pei zhen Cai	Director	2.8yrs	geen gegevens	geen gegevens
Shi Jun He	Independent Director	2.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 4123 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Center Laboratories Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Center Laboratories, Inc. Elects Directors

Recent updates

Center Laboratories, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: NT$0.10 loss per share (vs NT$1.43 loss in 2Q 2023)

Center Laboratories, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.43 per share

First quarter 2024 earnings released: NT$0.78 loss per share (vs NT$1.52 profit in 1Q 2023)

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc. to Report Q1, 2024 Results on May 13, 2024

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: NT$1.50 loss per share (vs NT$0.16 profit in FY 2022)

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: NT$1.49 loss per share (vs NT$1.68 loss in 3Q 2022)

Upcoming dividend of NT$0.99 per share at 1.9% yield

Second quarter 2023 earnings released: NT$1.57 loss per share (vs NT$0.31 loss in 2Q 2022)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023

Full year 2022 earnings released: EPS: NT$0.17 (vs NT$3.14 in FY 2021)

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Upcoming dividend of NT$2.43 per share

Second quarter 2022 earnings released: NT$0.36 loss per share (vs NT$2.42 profit in 2Q 2021)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021

Center Laboratories, Inc. Elects Directors

First quarter 2022 earnings released: EPS: NT$2.69 (vs NT$4.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$3.60 (vs NT$7.73 in FY 2020)

Center Laboratories, Inc., Annual General Meeting, May 20, 2022

Third quarter 2021 earnings released: NT$1.61 loss per share (vs NT$1.90 profit in 3Q 2020)

Upcoming dividend of NT$1.50 per share

Second quarter 2021 earnings released: EPS NT$2.66 (vs NT$2.88 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$4.63 (vs NT$0.48 in 1Q 2020)

Full year 2020 earnings released: EPS NT$8.50 (vs NT$0.68 loss in FY 2019)

Center Laboratories, Inc., Annual General Meeting, May 28, 2021

New 90-day low: NT$61.90

New 90-day high: NT$72.20

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Third quarter 2020 earnings released: EPS NT$2.09

New 90-day low: NT$65.20

New 90-day low: NT$68.70

First half earnings released

Upcoming Dividend of NT$1.43 Per Share

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur